Abstract
Despite recent advances in therapy, such as stem cell transplantation and new drugs including proteosome inhibitors, multiple myeloma (MM) remains incurable for most patients. Immune therapy using dendritic cell (DC) vaccination to generate anti-myeloma cytotoxic T cell (CTL) responses targeting residual disease is a promising, potentially curative strategy that would be compatible with other therapies. Blood DC isolated using the monoclonal antibody (mAb) CMRF-56, can induce CTL responses (
J. Immunotherapy
. 2005
; 28
:322
Author notes
Disclosure: No relevant conflicts of interest to declare.
2007, The American Society of Hematology
2007
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal